Codexis (CDXS) Insider Cynthia Collins Buys 66,350 Shares
Cynthia Collins acquired 66,350 shares of Codexis, Inc. on June 17, 2026.
Reviewed by automated data checks against the source filing. How we make and check alerts
Cynthia Collins bought 66,350 shares of Codexis, Inc. ($CDXS) on June 17, 2026. The trade was reported to the SEC in a Form 4 filing.
Since the trade, $CDXS is down 8.5% after 1 week, down 9.7% after 1 month and down 50.0% to date (from the $2.48 close on Jun 17, 2026).
CDXS
Codexis, Inc.
Key Points
- Cynthia Collins bought 66,350 shares of Codexis, Inc. on June 17, 2026, as an insider transaction.
- Codexis, Inc. trades at $2.48 with a market cap of $233.6 million and a forward P/E of -6.95.
- Institutional investors like BlackRock reduced their holdings in Codexis, while others like Millennium Management increased theirs.
Get $CDXS trade alerts by text
We text you when insiders, Congress or big funds trade $CDXS. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Codexis, Inc. alert may contain errors. Disclosures
On June 17, 2026, Cynthia Collins acquired 66,350 shares of Codexis, Inc. (NasdaqGS: CDXS). This insider purchase comes as the stock trades at $2.48.
Insider Buying and Selling at Codexis, Inc.
Cynthia Collins was not alone in her purchase on June 17, 2026. Other insiders, including Richards Christos, Parker Stewart, and Smith David, also bought 66,350 shares each. These transactions were not part of a pre-planned trading program.
Other Institutional Activity in Codexis, Inc.
Several institutional investors have adjusted their positions in Codexis. Aberdeen Group PLC increased its holdings by 713,870 shares, ending with 8,680,368 shares valued at about $14.1 million. Conversely, BlackRock, Inc. trimmed its stake by 366,967 shares, now holding 7,028,773 shares worth approximately $11.5 million. Millennium Management LLC boosted its position by 862,938 shares, reaching 3,998,130 shares valued at $6.5 million.
Codexis, Inc. Stock Up 89.0%
Shares of Codexis, Inc. are trading at $2.48. The company has a market capitalization of $233.6 million and a forward P/E ratio of -6.95, indicating it is not currently profitable. The stock's 52-week range is between $0.96 and $3.87, with a 50-day moving average of $2.57 and a 200-day moving average of $2.02. Codexis has a beta of 2.478, suggesting higher volatility compared to the market.
Analysts Set New Price Targets
Analysts have been active in setting price targets for Codexis. On August 29, 2024, Cantor Fitzgerald reiterated its buy rating with a target price of $11.0. Stifel Nicolaus maintained its buy rating, setting a target of $5.0 on May 20, 2024. Piper Sandler also reiterated a buy rating with a $10.0 target on April 26, 2024. Overall, the stock has a consensus recommendation of "buy" with a mean target price of $6.58.
About Codexis, Inc.
Codexis, Inc. is a biotechnology company based in Redwood City, California. It focuses on developing enzyme solutions for the manufacturing of therapeutics. Utilizing its proprietary CodeEvolver technology, Codexis enhances and commercializes novel enzymes. The company also works on its ECO Synthesis manufacturing platform, aiming to facilitate RNAi therapeutics production. Dr. Alison Moore leads the company as CEO, and Codexis operates globally across various regions.
Bottom Line
Cynthia Collins's insider purchase of Codexis shares highlights her confidence in the company's potential. Codexis, trading at $2.48, has seen mixed institutional interest, with some funds increasing and others decreasing their stakes. As analysts continue to provide optimistic price targets, investors will be watching closely. Remember, insider transactions are reported after the fact and might not reflect current positions.
Related Filing Alerts
Source: Cynthia Collins's Form 4 filing on $CDXS (Jun 17, 2026). Find the original filing: CDXS Form 4 filings on SEC EDGAR. Written by software, not financial advice. How we make alerts